Call 1-844-RAPIVAB or request information here. This site is intended for US health care professionals only | Important Safety Information | Prescribing Information

First-and-only ONE-DOSE IV treatment for influenza1

Rapivab — A new choice for your patients who could benefit from a single dose, IV treatment

The CDC recommends early treatment of influenza in patients who are at higher risk for complications, including:2

  • Patients with asthma
  • Patients with diabetes
  • Patients with heart disease and those who have had a stroke
  • Adults 65 and older
  • People who have HIV or AIDS
  • People who have cancer6

Rapivab may be suitable for influenza patients, including:

  • Patients presenting with nausea, vomiting, diarrhea, or other
    GI sensitivity
  • Patients also requiring IV placement for rehydration or other medications
  • Patients preferring a single-dose treatment administered by a healthcare provider
  • Patients who otherwise cannot be prescribed oral or inhaled,
    multi-dose therapies

Click here to view a case study and short video titled Treating Acute Uncomplicated Influenza with a Novel One-Dose Intravenous Neuraminidase Inhibitor.

Back to Top